Patent 8637641 was granted and assigned to Xencor on January, 2014 by the United States Patent and Trademark Office.
The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.